Hormone Therapy Delivery: Evidence‑Based Recommendations

1. Estrogen Therapy – Route Selection

• Transdermal estradiol is the preferred first‑line route because it bypasses hepatic first‑pass metabolism, thereby lowering the incidence of venous thromboembolism, hypertriglyceridemia, and gallbladder disease compared with oral formulations (American College of Endocrinology) 1.
• Oral estrogens undergo substantial first‑pass hepatic metabolism, producing marked inter‑individual variability in systemic levels (American College of Endocrinology) 2.
• Oral estradiol generates approximately 5‑fold higher circulating estrone and 10‑ to 20‑fold higher estrone‑sulfate than transdermal estradiol at equivalent doses; the clinical relevance of these metabolites remains uncertain 1.
• High hepatic estrogen concentrations after oral dosing stimulate increased synthesis of triglycerides, sex‑hormone‑binding globulin, cortisol‑binding globulin, angiotensinogen, and C‑reactive protein (American College of Endocrinology) 2.
• Oral formulations are convenient, extensively studied, and relieve menopausal symptoms in a dose‑dependent manner 1.
• Oral estrogens exhibit greater pro‑coagulant activity, raising coagulation and fibrinolysis markers 1.
• Oral estrogen raises triglyceride levels and is contraindicated in women with pre‑existing hypertriglyceridemia (American College of Endocrinology) 2.

2. Transdermal Estrogen – Pharmacology & Clinical Profile

• Transdermal delivery bypasses first‑pass hepatic metabolism, delivering estradiol directly to peripheral circulation and avoiding hepatic protein‑synthesis alterations (American College of Endocrinology) 2.
• Transdermal preparations have neutral or minimal effects on coagulation factors, inflammatory markers, triglycerides, and binding proteins 1.
• Efficacy for relief of menopausal symptoms is comparable to oral estrogen, and dosing can be readily titrated 1.
• Transdermal estradiol is specifically recommended for women with venous thromboembolism risk, hypertension, hypertriglyceridemia, obesity, metabolic syndrome, diabetes, or a history of gallbladder disease (supported by meta‑analysis) 3.

3. Transdermal Formulations – Practical Considerations

• Skin patches may cause local irritation and adhesion problems (Gastroenterology) 4.
• Topical gels can be unintentionally transferred to contacts through prolonged skin contact (Gastroenterology) 4.
• Absorption from gels can be variable, leading to inconsistent hormone exposure in some patients (Gastroenterology) 4.
• Transdermal therapy may be safe in women with prior thromboembolism or thrombogenic mutations, although many authorities still list prior thromboembolism as an absolute contraindication (American College of Endocrinology) 2.

4. Testosterone Therapy – Route Selection

• Weekly intramuscular testosterone cypionate (75–100 mg) provides more stable serum concentrations with less peak‑trough fluctuation and is superior for maintaining levels within the therapeutic range (Annals of Internal Medicine) 5.
• Transdermal testosterone (gel or patch) is recommended as first‑line because it yields physiologic serum concentrations with day‑to‑day stability and is preferred by most patients (Gastroenterology) 4.
• Injectable testosterone is less expensive than transdermal preparations (Gastroenterology) 4.
• Injectable testosterone may be considered for men who prefer less frequent dosing, have cost constraints, or demonstrate poor gel absorption (Annals of Internal Medicine) 5.

5. Monitoring Pitfalls – Estrogen & Testosterone

• Serum follicle‑stimulating hormone (FSH) should not be used to gauge adequacy of estrogen replacement, because FSH can remain elevated despite sufficient tissue estrogen effect (American College of Endocrinology) 2.

6. Clinical Decision Algorithms

Estrogen Therapy

Testosterone Therapy

All statements are derived from peer‑reviewed evidence with citation identifiers as indicated.

Transdermal Estradiol and Progestogen Use in Menopausal Hormone Therapy

Efficacy and Safety of Transdermal Estradiol

• Transdermal estradiol produces neutral effects on coagulation factors, inflammatory markers (C‑reactive protein), and binding proteins such as SHBG and thyroid‑binding globulin, indicating a favorable metabolic profile compared with oral or injectable estrogens. 6
• Symptom relief for vasomotor complaints and genitourinary atrophy with transdermal estradiol is comparable to that achieved with oral or injectable formulations, while allowing easier dose titration. 6

Indications for the Transdermal Route

• The American College of Endocrinology recommends transdermal estradiol as the preferred route for women who have any of the following risk factors: venous thromboembolism (VTE), hypertension, hypertriglyceridemia, obesity, metabolic syndrome, diabetes, or a history of gallbladder disease. 7
• Transdermal estradiol is endorsed as first‑line therapy for menopausal hormone treatment because of its lower metabolic and thrombotic risk profile. 7

Progestogen Requirements for Endometrial Protection

• In women with an intact uterus, a progestogen must be added to estrogen therapy to prevent endometrial hyperplasia and cancer. 7
• Sequential micronized progesterone 200 mg taken orally for 12–14 days each month provides complete endometrial protection with the fewest side‑effects, particularly regarding mood. 8
• Medroxyprogesterone acetate should be avoided in patients with mood concerns, as it commonly worsens mood swings, bloating, and sleep disturbance. 8

Monitoring Strategies

• Serum follicle‑stimulating hormone (FSH) levels are not useful for assessing adequacy of estrogen replacement because FSH remains elevated even when tissue estrogen effect is sufficient. 8
• Serum estradiol measurement should be reserved for situations where vasomotor or genitourinary symptoms do not improve despite dose escalation, or after a change in delivery route (e.g., oral to transdermal). 6

Oral Estradiol as an Alternative When Transdermal Is Not Feasible

• Oral estradiol 1–2 mg daily is an acceptable alternative for women who cannot use transdermal therapy and have no contraindicating cardiovascular or metabolic risk factors. [6][7]

All bullet points are based on cited evidence and reflect guideline‑level recommendations where indicated.

Hormone Pellet Use in Women – Guideline Recommendations

General Recommendations

• Hormone pellets (both estrogen and testosterone) are not recommended as first‑line therapy because of the risk of supraphysiologic dosing, wide pharmacokinetic variability, and insufficient safety data; they may be considered only for selected patients who cannot tolerate or absorb standard transdermal formulations. 9

Testosterone Pellet Guidance

• The Global Consensus Position Statement advises against testosterone pellets since they generate supraphysiologic testosterone concentrations that exceed the physiologic premenopausal female range. 9
• Testosterone therapy in women is evidence‑based solely for hypoactive sexual desire disorder (HSDD) in postmenopausal women after a formal biopsychosocial assessment, and hormone levels must be kept within the physiologic female range. (Evidence level: moderate) 9
• Compounded “bioidentical” testosterone preparations, including pellets, cannot be recommended due to a lack of efficacy and safety evidence. (Evidence level: low) 9
• Pellets should not be used as first‑line therapy; they are reserved for women who have failed or cannot use transdermal formulations. (Evidence level: moderate) 9
• Current evidence does not support routine use of testosterone pellets in women because of supraphysiologic dosing and the absence of long‑term safety data. (Evidence level: low) 9

Monitoring Recommendations (if pellets are used off‑label)

• Baseline assessment: Measure total testosterone before pellet insertion. 9
• Early follow‑up: Re‑measure total testosterone 3–6 weeks after insertion to assess the early peak. 9
• Ongoing surveillance: Monitor testosterone levels every 6 months for signs of androgen excess and to detect over‑use. 9
• Target range: Maintain total testosterone within the premenopausal physiologic range (< 55 ng/dL); levels above this threshold require dose reduction or discontinuation. (Evidence level: low) 9
• Therapeutic trial: Discontinue testosterone pellet therapy if the patient experiences no clinical benefit by 6 months. (Evidence level: low) 9